



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/978,360	10/15/2001	Jean-Baptiste Dumas Milne Edwards	G-056US04CIP	4722

23557 7590 12/15/2004

SALIWANCHIK LLOYD & SALIWANCHIK  
A PROFESSIONAL ASSOCIATION  
PO BOX 142950  
GAINESVILLE, FL 32614-2950

EXAMINER

O HARA, EILEEN B

ART UNIT	PAPER NUMBER
----------	--------------

1646

DATE MAILED: 12/15/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

**Application No.**

09/978,360

**Applicant(s)**

DUMAS MILNE EDWARDS ET AL.

**Examiner**

Eileen O'Hara

**Art Unit**

1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 27 September 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-13 is/are pending in the application.
- 4a) Of the above claim(s) 1 and 3-13 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 2 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-13 ~~are~~ <sup>will</sup> be subject to restriction and/or election requirement.

**Application Papers**

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 15 October 2001 is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☒ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date 2/04/02 & 9/27/04
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_

***Response to Amendment***

1. Claims 1-13 are pending in the instant application.

***Election/Restrictions***

2. Applicant's election without traverse of Group II, claim 2, and polypeptide of SEQ ID NO: 437 in the reply filed on Sept. 27, 2004 is acknowledged.

Claims 1 and 3-13 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. XX.

Claim 2 is currently under examination.

***Priority***

3. Applicant is reminded of the following requirement:

In a continuation or divisional application (other than a continued prosecution application filed under 37 CFR 1.53(d)), the first sentence of the specification or application data sheet (37 CFR 1.76) should include a reference to the prior application(s) from which benefit of priority is claimed, and also the status. See 37 CFR 1.78. The status of application 09/663,600 should be updated (now U.S. Patent No. 6,573,068).

***Specification***

4. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed.

The following title is suggested: Zinc Finger Binding Protein NO: 437.

Art Unit: 1646

***Claim Objections***

5. Claim 2 is objected to because of the following informalities: it recites non-elected inventions. Appropriate correction is required.

***Claim Rejections - 35 USC § 101***

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

6. Claim 2 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. Claim 2, as written, does not sufficiently distinguish over the polypeptide as it exists naturally because the claim does not particularly point out any non-naturally occurring differences between the claimed products and the naturally occurring products. In the absence of the hand of man, the naturally occurring products are considered non-statutory subject matter. See *Diamond v. Chakrabarty*, 447 U.S. 303, 206 USPQ 193 (1980). The claim should be amended to indicate the hand of the inventor, e.g., by insertion of “isolated” or “purified”. See MPEP 2105.

***Claim Rejections - 35 USC § 101 and § 112***

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

7. Claim 2 is rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility. Claim 2 is

Art Unit: 1646

directed to the protein of SEQ ID NO: 437. The instant specification discloses that the protein of SEQ ID NO: 437 is a 352 amino acid protein, and that it shows homology with zinc binding proteins, and exhibits the pfam RING zinc finger signature from positions 302-339. However, the protein does not have any specific and substantial utility, or a well established utility, as determined according to the current Utility Examination Guidelines, Federal Register, Vol. 66, No. 4, pages 1092-1099, Friday, January 5, 2001.

The instant application states that it is believed that the protein of SEQ ID NO: 437 or part thereof is a zinc binding protein, preferably able to bind to nucleic acids or proteins, more preferably a transcription factor (page 82, lines 29-30). The specification also states that other preferred polypeptides of the invention are fragments of SEQ ID NO: 437 having any of the biological activity described herein, and that the nucleic acid binding activity of the protein of the invention or part thereof may be assayed using any of the assays known to those skilled in the art including those described in US patent 6,013,453 (page 82, lines 32-35). On page 83, the specification further describes methods of immobilizing the protein, such as on a chromatographic support, and use to isolate and identify nucleic acids that would bind the protein, or methods of using the protein to alter the expression of genes of interest in target cells, and that such genes may be disease related genes, such as oncogenes or exogenous genes from pathogens. Also contemplated in use of the protein to diagnose treat and/or prevent disorders linked to dysregulation of gene transcription, and list a number of diseases/disorders on page 83, lines 27-29.

Activities of the protein, such as generating antibodies, or use in assays to discover what protein would bind to it, or use to identify biological activities, are general activities that would

Art Unit: 1646

apply to any protein, and are not specific and substantial. Use of a putative nucleic acid binding protein (transcription factor) to identify possible nucleic acids it would bind is also not a specific and substantial, and would apply to any protein in families that bind nucleic acids. None of these uses are considered to be specific or substantial utilities for the protein. There is no evidence presented or statement made that the protein binds to any specific nucleic acid sequence or protein. Use of the protein in bioassays is also not a specific and substantial utility, and is only further research to discover what the activities and biological significance of the protein is.

The instant application also teaches that the protein can be used either diagnostically, or therapeutically to treat diseases or disorders, such as those listed on page 83, including cancer, hypocortisolism, gastritis and Crohn's disease, among others. However, the assertions that the protein and/or nucleic acids of the instant invention can be used in the diagnosis or treatment of diseases or disorders, are based on the assumption that the protein is a transcription factor, based on the presence of a zinc finger motif. Transcription factors are involved in myriad biological pathways, activities and disorders, and activate specific genes, and it is not predictable what activity any transcription factor has. Many proteins are members of evolutionarily related families, yet have diverse biological activities and functions. Clarke and Berg teach that more than 3 percent of the protein sequences inferred from the *Caenorhabditis elegans* genome contain sequence motifs characteristic of zinc-binding structural domains, and of these more than half are believed to be sequence-specific DNA-binding proteins. The literature teaches that the zinc finger protein family is extremely large, and is specific as to what nucleic acid sequences such proteins bind and regulate. There is no nucleic acid sequence that the protein of the instant invention is known to bind, and no specific biological activities disclosed.

Art Unit: 1646

There additionally is no nexus between any of the diseases or disorders and the protein of the instant invention. Given no disease state or any other function or activity known for the protein, the protein is not considered to have utility. In *Brenner v. Manson*, 148 U.S.P.Q. 689 (Sus. Ct., 1966), a process of producing a novel compound that was structurally analogous to other compounds which were known to possess anti-cancer activity was alleged to be useful because the compound produced thereby was potentially useful as an anti-tumor agent in the absence of evidence supporting this utility. The court expressed the opinion that all chemical compounds are “useful” to the chemical arts when this term is given its broadest interpretation. However, the court held that this broad interpretation was not the intended definition of “useful” as it appears in 35 U.S.C. § 101, which requires that an invention must have either an immediately obvious or fully disclosed “real world” utility. The instant claim is drawn to a protein which has undetermined function or biological significance, and the use of protein to discover its properties does not constitute a specific, substantial utility. All of the biological activities of a protein need not be known to obtain a patent, but there must be some specific and substantial activity or function known. It is possible that after further characterization, this protein might be found to have a patentable utility, such as association with a specific disease. This further characterization, however, is part of the act of invention, and until it has been undertaken the Applicants’ claimed invention is incomplete.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

8.1 Claim 2 is also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention. Even if the specification were enabling of how to use the polypeptide of SEQ ID NO: 437, enablement would not be found commensurate in scope with the claims. If one of skill in the art does not know how to use the polypeptide of SEQ ID NO: 437, the skilled artisan would clearly not know how to use polypeptides comprising fragments of the polypeptide of SEQ ID NO: 437 or fragments thereof.

8.2 Claim 2 is also rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The specification describes a polypeptide having the sequence consisting of SEQ ID NO: 437 and encoding nucleic acid. However, the claims as written include polypeptides comprising fragments and homologues, encompass polypeptides that vary substantially in length and also in amino acid composition. The instant disclosure of one polypeptide, does not adequately support the scope of the claimed genus, which encompasses a substantial variety of subgenera. A genus claim may be supported by a representative number of species as set forth in *Regents of the University of California v Eli Lilly & Co*, 119F3d 1559, 1569, 43 USPQ2d 1398, 1406 (Fed. Cir. 1997), which states:

“To fulfill the written description requirement, a patent specification must describe an invention and do so in sufficient detail that one skilled in the art can clearly conclude that “the inventor invented the claimed invention”. Lockwood v. American Airlines, Inc., 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (1997); In re Gosteli, 872 F.2d 1008, 1012, 10 USPQ2d 1614,



Art Unit: 1646

1618 (Fed. Cir. 1980) (“[T]he description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed.”) Thus, an applicant complies with the written description requirement “by describing the invention, with all its claimed limitations, not that which makes it obvious,” and by using “such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention.” Lockwood, 107 F.3d 1565, 1572, 41 USPQ2d at 1966.

An adequate written description of a DNA, such as the cDNA of the recombinant plasmids and microorganisms of the ‘525 patent, “requires a precise definition, such as by structure, formula, chemical name, or physical properties,” not a mere wish or plan for obtaining the claimed chemical invention. Fiers v. Revel, 984 F.2d 1164, 1171, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993). Accordingly, “an adequate written description of a DNA requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it; what is required is a description of the DNA itself.” Id at 1170, 25 USPQ2d at 1606.”

A description of a genus of cDNAs may be achieved by means of a recitation of a representative number of cDNAs, defined by nucleotide sequence, falling within the scope of the genus, or of a recitation of structural features common to the genus, which features constitute a substantial portion of the genus. The instant specification discloses, however, a single isolated polypeptide sequence SEQ ID NO: 437. Protein function, however, cannot be reliably predicted from protein sequence homology. For example, Transforming Growth Factor (TGF-beta) Family OP-1 induces metanephrogenesis whereas closely related TGF-beta family members-BMP-2 and TGF-beta1-have no effect on metanephrogenesis under identical conditions (Vukicevic et al., 1996, PNAS USA 93:9021-9026). Platelet-derived Growth Factor (PDGF) Family VEGF, a member of the PDGF family, is mitogenic for vascular endothelial cells but not for vascular smooth muscle cells while PDGF is mitogenic for vascular smooth muscle cells but not for vascular endothelial cells (Tischer et al., U.S. Patent 5,194,596, column 2, line 46 to column 3,

Art Unit: 1646

line 2). Finally, vertebrate growth hormone of 198 amino acids becomes an antagonist (inhibitor of growth) when a single amino acid is changed (Kopchick et al, U.S. Patent No. 5,350,836).

Even 99% homology does not allow predictability in this instance. Given the unpredictability of homology comparisons, and the fact that the specification fails to provide objective evidence that the additional sequences are indeed species of the claimed genus it cannot be established that a representative number of species have been disclosed to support the genus claim. No activity is set forth for the additional sequences. The instantly claimed genus is not so limited and the prior art does not provide compensatory structural or correlative teachings to enable one of skill to identify the polypeptides encompassed.

8.3 Claim 2 is also rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Claim 2 (a-d) encompasses a polynucleotide encoded by a human cDNA of a deposited clone.

Applicants referral to the ECACC deposit having an accession No. 98121805 and named SignalTag 166-191, on pages 20 and 39 of the specification is an insufficient assurance that all of the conditions of 37 CFR sections 1.801 through 1.809 have been met. If the deposits were made under the provisions of the Budapest Treaty, filing of an affidavit or declaration by applicants, assignees or a statement by an attorney of record over his or her signature and registration number stating that the deposits have been accepted by an International Depository Authority under the provisions of the Budapest Treaty, that all restrictions upon public access to the deposits will be irrevocably removed upon the grant of a patent on this application and that the deposit will be replaced if viable samples cannot be dispensed by the depository is required. This

Art Unit: 1646

requirement is necessary when deposits are made under the provisions of the Budapest Treaty as the Treaty leaves these specific matters to the discretion of each State.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

9. Claim 2 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 2 is indefinite because it recites in section (a) “any single integer from 6 to 500 amino acids”, and it is not clear what is meant by this. This reads on a polypeptide comprising an amino acid sequence consisting of a single integer of from amino acid 6 to 500 of SEQ ID NO: 437, so it reads on a polypeptide comprising an amino acid sequence of one amino acid of SEQ ID NO: 437. The specification on pages 17 and 152-153 discusses fragments of the polypeptides as comprising amino acids as integers ranging from amino acid 6 to the end of the C-terminal, and encompasses antigenic fragments. This considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired.

***Priority Determination***

35 U.S.C. § 120 states that:

An application for patent for an invention disclosed in the manner provided by the first paragraph of section 112 of this title in an application previously filed in the United States, or as provided by section 363 of this title, which is filed by an inventor or inventors named in the previously filed application shall have the same effect, as to such invention, as

Art Unit: 1646

though filed on the date of the prior application, if filed before the patenting or abandonment of or termination of proceedings on the first application or on an application similarly entitled to the benefit of the filing date of the first application and if it contains or is amended to contain a specific reference to the earlier filed application.

10. Applicant is advised that the instant application can only receive benefit under 35 U.S.C. § 120 from an earlier application which meets the requirements of 35 U.S.C. § 112, first paragraph, with respect to the now claimed invention. Because the instant application does not meet the requirements of 35 U.S.C. § 112, first paragraph, for those reasons given above and it is a continuation in part of application Serial Number 09/663,500, the prior application does not meet those requirements and, therefore, is unavailable under 35 U.S.C. § 120. The effective priority date of the instant application is considered to be the filing date of this application, October 15, 2001, because the claimed invention is not supported by either a specific and substantial utility or a well established utility.

### ***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

11.1 Claim 2 is rejected under 35 U.S.C. 102(a) as being anticipated by Kato et al.,  
WO200149728, July 12, 2001.

Art Unit: 1646

Claim 2 encompasses a polypeptide comprising an amino acid of SEQ ID NO: 437, further comprising a physiologically acceptable carrier.

Kato et al. disclose a polypeptide (SEQ ID NO: 92) that is 100% identical to the protein of SEQ ID NO: 437 of the instant invention. Although Kato et al. is silent with respect to the polypeptide further comprising a physiologically acceptable carrier, Kato et al. state that the protein can be used to generate antibodies by immunizing animals, so that the protein would by necessity be in a physiologically acceptable carrier (page 21). Kato et al. also teach administration of the proteins (paragraphs bridging pages 21-22). Therefore, Kato et al. anticipates the claim.

11.2 Claim 2 is rejected under 35 U.S.C. 102(e) as being anticipated by Rosen et al., U.S.

Published Application No. 20020132753, filing date Jan. 17, 2001.

Rosen et al. disclose a polypeptide (SEQ ID NO: 801) that is 100% identical to the protein of SEQ ID NO: 437 of the instant invention. Rosen et al. also teach that the protein can also comprise a pharmaceutically (physiologically) acceptable carrier (paragraph 0321).

Therefore, Rosen et al. anticipates the claim.

### ***Conclusion***

12. No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eileen B. O'Hara, whose telephone number is (571) 272-0878. The examiner can normally be reached on Monday through Friday from 10:00 AM to 6:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached at (571) 272-0961.

Art Unit: 1646

The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://portal.uspto.gov/external/portal/pair>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).

Eileen B. O'Hara, Ph.D.

Patent Examiner



EILEEN B. O'HARA  
PATENT EXAMINER